Biopharmaceutical company focused on developing therapeutic treatments for G protein-coupled receptors (GPCRs).
Structure Therapeutics Inc., headquartered in South San Francisco, California, is a global biopharmaceutical company in the clinical stage, specializing in the development of innovative oral therapeutics for chronic diseases with significant unmet medical needs. Established in 2016 and previously known as ShouTi Inc., the company is dedicated to advancing treatment options for conditions such as type-2 diabetes mellitus, obesity, pulmonary diseases, and cardiovascular disorders.
At the forefront of Structure Therapeutics' pipeline is GSBR-1290, a promising oral small molecule agonist of the glucagon-like-peptide-1 receptor (GLP-1R). This compound targets a validated drug target within the G-protein-coupled receptors (GPCRs) family, addressing critical aspects of diabetes and obesity management. Additionally, the company is actively developing ANPA-0073, a biased agonist targeting the apelin receptor, implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension, as well as LTSE-2578, an investigational oral lysophosphatidic acid 1 receptor antagonist aimed at treating IPF.
Driven by a commitment to scientific innovation and therapeutic advancement, Structure Therapeutics combines rigorous research with strategic development initiatives. The company's comprehensive approach underscores its mission to deliver transformative therapies that improve patient outcomes and address complex medical challenges globally. Positioned within the biopharmaceutical hub of South San Francisco, Structure Therapeutics continues to expand its capabilities and forge collaborations aimed at accelerating the development of novel treatments for chronic diseases.